Cell Biotech Co., Ltd. (KOSDAQ: 049960)

Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	13,474	7,884	8,458	9,860	9,600	9,422
Short-Term Investments	49,720	56,515	37,671	18,675	23,084	25,388
Trading Asset Securities	16,461	5,933	19,239	29,299	22,203	24,413
Cash & Short-Term Investments	79,655	70,332	65,368	57,834	54,887	59,224
Cash Growth	17.33%	7.59%	13.03%	5.37%	-7.32%	-4.73%
Accounts Receivable	3,893	4,595	4,566	4,664	4,835	4,857
Other Receivables	1,018	943.86	583.11	268.43	283.39	367.36
Receivables	5,119	5,740	5,330	5,216	5,557	5,495
Inventory	4,102	4,122	4,102	3,589	3,503	3,076
Prepaid Expenses	190.49	691.85	500.5	292.5	218.67	233.3
Other Current Assets	236.48	1,044	354.58	587.81	746.72	1,230
Total Current Assets	89,303	81,929	75,655	67,519	64,913	69,258
Property, Plant & Equipment	31,050	32,937	33,638	34,057	36,602	36,065
Long-Term Investments	501.94	501.94	3,786	8,427	2	2
Other Intangible Assets	1,655	1,599	1,793	1,536	1,802	1,702
Long-Term Accounts Receivable	-0	0	0	0	0	0
Long-Term Deferred Tax Assets	182.29	182.29	449.3	751.56	1,395	579.45
Other Long-Term Assets	505.34	491.37	517.21	585.15	587.54	697.27
Total Assets	123,197	117,641	115,839	112,877	105,301	108,303
Accounts Payable	393.61	578.39	1,370	1,224	887.65	1,009
Accrued Expenses	1,278	489.15	443.91	470.95	496.32	432.87
Current Portion of Leases	662.27	621.14	600.78	402.89	658.65	413.04
Current Income Taxes Payable	928.89	-	1,038	814.73	-	-
Current Unearned Revenue	28.3	27.03	30.9	50.44	41.52	31.19
Other Current Liabilities	2,178	3,106	3,905	2,802	2,546	2,302
Total Current Liabilities	5,468	4,821	7,389	5,766	4,630	4,189
Long-Term Leases	520.06	934.17	357.79	423.49	686.44	512.08
Other Long-Term Liabilities	-	-	-	0	-	-
Total Liabilities	5,988	5,755	7,747	6,189	5,317	4,701
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	12,760	12,760	12,760	12,760	12,760	12,760
Retained Earnings	123,404	118,217	114,993	109,894	102,696	103,848
Treasury Stock	-23,978	-23,978	-23,978	-20,258	-20,258	-17,652
Comprehensive Income & Other	322.36	186.4	-382.91	-408.42	86.97	-53.66
Shareholders' Equity	117,209	111,885	108,092	106,687	99,985	103,602
Total Liabilities & Equity	123,197	117,641	115,839	112,877	105,301	108,303
Total Debt	1,182	1,555	958.57	826.38	1,345	925.13
Net Cash (Debt)	78,473	68,777	64,409	57,007	53,542	58,299
Net Cash Growth	18.58%	6.78%	12.98%	6.47%	-8.16%	-6.22%
Net Cash Per Share	11466.11	10049.37	9342.06	8061.43	7547.42	7868.29
Filing Date Shares Outstanding	6.84	6.84	6.84	7.07	7.07	7.23
Total Common Shares Outstanding	6.84	6.84	6.84	7.07	7.09	7.41
Working Capital	83,835	77,108	68,266	61,754	60,283	65,069
Book Value Per Share	17126.03	16348.17	15793.91	15086.68	14094.07	13982.73
Tangible Book Value	115,554	110,286	106,299	105,151	98,183	101,901
Tangible Book Value Per Share	16884.23	16114.53	15531.88	14869.49	13840.05	13753.04
Land	9,696	9,765	9,765	9,765	9,784	8,866
Buildings	12,751	13,063	13,349	13,854	14,389	12,316
Machinery	6,159	7,060	7,228	8,033	9,682	9,481
Construction In Progress	367.3	338.95	993.9	247.26	95	3,348

Source: S&P Capital IQ. Standard template. Financial Sources.